



The Nutrition Society Winter Conference was held at the Royal Society of Medicine, London on 5–6 December 2017

Conference on ‘Diet, nutrition and the changing face of cancer survivorship’ International Nutrition Student Research Championship 2017 Programme

Generating the evidence for risk reduction: a contribution to the future of food-based dietary guidelines

Lukas Schwingshackl^{1,2*}, Sabrina Schlesinger³, Brecht Devleesschauwer⁴, Georg Hoffmann⁵, Angela Bechthold⁶, Carolina Schwedhelm^{1,2}, Khalid Iqbal¹, Sven Knüppel¹ and Heiner Boeing^{1,2}

¹Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany

²NutriAct – Competence Cluster Nutrition Research Berlin-Potsdam, Nuthetal, Germany

³Institute for Biometry and Epidemiology, German Diabetes Center, Leibniz Institute for Diabetes Research at the Heinrich-Heine-University Düsseldorf, D-40225 Düsseldorf, Germany

⁴Department of Public Health and Surveillance, Scientific Institute of Public Health, Rue Juliette Wytsmanstraat 14, 1050 Brussels, Belgium

⁵Department of Nutritional Sciences, University of Vienna, Althanstraße 14, UZA II, 1090 Vienna, Austria

⁶German Nutrition Society, Godesberger Allee 18, 53175 Bonn, Germany

A major advantage of analyses on the food group level is that the results are better interpretable compared with nutrients or complex dietary patterns. Such results are also easier to transfer into recommendations on primary prevention of non-communicable diseases. As a consequence, food-based dietary guidelines (FBDG) are now the preferred approach to guide the population regarding their dietary habits. However, such guidelines should be based on a high grade of evidence as requested in many other areas of public health practice. The most straightforward approach to generate evidence is meta-analysing published data based on a careful definition of the research question. Explicit definitions of study questions should include participants, interventions/exposure, comparisons, outcomes and study design. Such type of meta-analyses should not only focus on categorical comparisons, but also on linear and non-linear dose–response associations. Risk of bias of the individual studies of the meta-analysis should be assessed, rated and the overall credibility of the results scored (e.g. using NutriGrade). Tools such as a measurement tool to assess systematic reviews or ROBIS are available to evaluate the methodological quality/risk of bias of meta-analyses. To further evaluate the complete picture of evidence, we propose conducting network meta-analyses (NMA) of intervention trials, mostly on intermediate disease markers. To rank food groups according to their impact, disability-adjusted life years can be used for the various clinical outcomes and the overall results can be compared across the food groups. For future FBDG, we recommend to implement evidence from pairwise and NMA and to quantify the health impact of diet–disease relationships.

Meta-analysis: Evidence: Food-based dietary guidelines

Abbreviations: DALY, disability-adjusted life years; FBDG, food-based dietary guidelines; FG, fasting glucose; GBD, global burden of disease; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; NMA, network meta-analysis; PAF, population-attributable fractions; RCT, randomised controlled trials; SBP, systolic blood pressure; SSB, sugar-sweetened beverages; TC, total cholesterol; T2D, type 2 diabetes.

*Corresponding author: Lukas Schwingshackl, email lukas.schwingshackl@dife.de



Background

Lifestyle is a crucial factor in the prevention of non-communicable diseases. Large long-term prospective cohort studies have shown that 60–75 % of coronary events and 36 % of cancer incidences can be explained by modifiable risk factors such as unhealthy diets, overweight, obesity, physical inactivity, smoking and excessive alcohol intake^(1,2). According to the most recent report by the global burden of disease (GBD) 2016 study, an unhealthy diet is a leading risk factor for premature death and disability worldwide⁽³⁾. Dietary risk factors were associated with nearly 10 % of the GBD⁽³⁾.

Research to reduce dietary risk should address the level of consumption of food groups in combination with nutrients and other dietary compounds. A major advantage of analyses on the food group level is that the results are better interpretable compared with nutrients or complex dietary patterns, and therefore easier to transfer into recommendations on primary prevention of non-communicable disease, including CVD, type 2 diabetes (T2D), hypertension and different cancer types. A major approach to reduce non-communicable diseases in a population by modifying food intake is directly linked to the concept of food-based dietary guidelines (FBDG)^(4,5). FBDG are the preferred approach to guide the population regarding their dietary habits. However, such guidelines should be based on a high grade of evidence as requested in many other areas of public health practice.

An adequate approach to clarify inconclusive data and knowledge in the field of public health nutrition is to systematically review and meta-analyse the published data in order to further strengthen our understanding of the interplay between lifestyle, diet and health⁽⁶⁾. However, the issue of quality of such systematic reviews with quantitative meta-analyses is getting more and more into the focus. The widespread implementation of meta-analyses is a novel phenomenon and the standards of its application not always well known^(7,8).

To close the gap between the evidence generated by meta-analyses and the often direct transfer of such evidence into recommendations, a careful implementation of the systematic review and meta-analysis methods is needed. This is particularly important for the dietary recommendations such as the FBDG that often address disease reduction as the aim.

Thus, in this paper, we will summarise the methodological background of meta-analyses with dietary variables, the evaluation of risk of bias and the methods to assess the quality of evidence. The focus is given to meta-analyses on food and food groups. We will also highlight the evidence in this field generated by meta-analyses of randomised controlled trials (RCT) with the new option of network analyses and the evidence generated by observational studies. The concept of disability-adjusted life year (DALY) will be proposed as a method to quantify the food–disease relation across various health outcomes and to rank the results in terms of level of impact.

Generating the evidence for food-based dietary guidelines

General methodological background and standards of meta-analyses

During past decades, the number of systematic reviews with impact quantification has remarkably increased and they continue to replace narrative reviews previously used to combine data from multiple studies. Narrative reviews are often characterised by a lack of transparency and are therefore inherently subjective⁽⁹⁾. With the tremendous increase of scientific publications⁽¹⁰⁾, the methodology of narrative reviews has become less useful and systematic approaches have become the preferred option. Systematic reviews are described as comprehensive and objective summaries of all relevant high-quality research evidence addressing precise questions⁽¹¹⁾. In all fields of health sciences including nutritional sciences, systematic reviews have become an important tool for the evaluation of intervention trials and the transfer of the results into evidence-based science/medicine. The use of systematic reviews and meta-analyses to investigate lifestyle-related topics is also becoming increasingly popular due to the accumulation of scientific data in the course of the past years⁽¹²⁾.

To avoid flooding the media with poorly conducted systematic reviews and meta-analyses, as already has been criticised⁽⁷⁾, researchers should comply with distinct guidelines that ensure high-quality results when using this technique.

The Cochrane handbook defined five key characteristics for systematic reviews⁽¹¹⁾: (1) A clearly stated set of objectives with pre-defined eligibility criteria for studies; (2) An explicit, reproducible methodology; (3) A systematic search that attempts to identify all studies that would meet the eligibility criteria; (4) An assessment of the validity of the findings of the included studies, e.g. through the assessment of risk of bias; (5) A systematic presentation and synthesis of the characteristics and findings of the included studies.

Authors of systematic reviews and meta-analyses of RCT are encouraged to follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines⁽¹³⁾, while the appropriate tool for systematic reviews and meta-analyses of observational studies is the Meta-analysis of Observational Studies in Epidemiology checklist⁽¹⁴⁾. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement consists of a twenty-seven-item checklist and a four-phase flow diagram. A particularly important Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist point includes an explicit statement of study questions being addressed with reference to participants, interventions/exposure, comparisons, outcomes and study design. [Table 1](#) demonstrates an example from a previously published meta-analysis using the participants, interventions/exposure, comparisons, outcomes and study design criteria regarding the research question: Which dietary approach offers the greatest benefits in the management of glycaemic control in T2D patients^(15,16).

Systematic reviews are a form of observational research, and the methods for the review should be agreed on before

Table 1. Example for the application of the participants, interventions/exposure, comparisons, outcomes and study design criteria regarding the research question: Which dietary approach offers the greatest benefits in the management of glycaemic control in type 2 diabetes (T2D) patients?^(15,16)

Parameter	Description
Participants	Participants that are aged ≥ 18 years and are diagnosed with T2D using the diagnosis criteria of the American diabetes association or other internationally recognised standards
Interventions/ exposure	Eligible types of intervention diets will be the following: Low-carbohydrate diet (carbohydrates provide $<30\%$ total energy intake, high intake of animal and/or plant protein, often high intake of fat); low-fat diet (fat provide $<30\%$ of total energy intake, high intake of cereals and grains); vegetarian diet (no meat, poultry and fish)
Comparison	Control diet: no intervention or minimal intervention
Outcome	The primary outcome will be glycosylated Hb (HbA1c); the following secondary outcome will be considered: fasting plasma glucose
Study design	Randomised parallel or cross-over studies comparing different dietary approaches with a minimum intervention period of 3 months

the review commences. Recording a detailed protocol of each systematic review is an essential part of manuscript submission now required by most peer-reviewed journals. This can take the form of registration (e.g. at PROSPERO – <https://www.crd.york.ac.uk/PROSPERO/>), an open publication journal (e.g. *BMJ Open* or *Systematic Reviews*) or a dated submission to a research office or research ethics board. Adherence to a well-developed protocol reduces the risk of bias in the systematic review. Other important items of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist include: the presentation of full electronic search strategy of at least one database; study selection process; data extraction process; assessment of risk of bias; description of methods to handle data and combine results; reporting of evidence synthesis and additional analyses; summary of the main findings and strength of the evidence; and reporting of sources of funding⁽¹³⁾.

Statistical heterogeneity in a meta-analysis refers to variations in study estimates between the included studies, and may be due to variability in the participants, interventions, outcomes studied or methodological diversity. To explore statistical heterogeneity between studies, the Cochrane Q test and the I^2 statistic are important formal tests⁽¹¹⁾. Moreover, it is recommended to calculate the 95 % CI for the estimates of heterogeneity⁽¹⁷⁾. A value for $I^2 > 50\%$ is considered to represent substantial heterogeneity⁽¹¹⁾. Important strategies to investigate the sources of statistical heterogeneity include subgroup analysis (e.g. by sex, age, length of follow-up, geographic location and dietary assessment methods), meta-regression and sensitivity analysis for low risk of bias studies.

Another important issue of meta-analyses are small study effects, since smaller trials often report larger treatment effects compared with larger trials. Publication bias may be one of the reasons, since significant results are more likely submitted by authors and accepted by peer-reviewed journals even if these results come from small trials. Publication bias and small study effects can be explored visually by checking funnel plot for symmetry and by applying formal tests, including the Egger's and Begg's test^(11,18,19).

The observed effects in a study might be distorted by dependencies that could arise when comparing several treatment groups with one control group or several categories of exposures with one reference category. Such within-study dependence of measures of effect should be addressed in treatment comparisons and dose-response analyses using approaches proposed for multivariate meta-analysis^(20–22). However, adjustments for such correlated measures of effect are often overlooked in practice.

Specific features of meta-analyses of randomised controlled trials

In RCT of dietary interventions the most common measures of effect are the absolute differences of the mean value of a continuous outcome variable between two groups (intervention group and control group). If studies measure the outcome on different scales, the results have to be standardised to a uniform scale and the standardised mean difference has to be used⁽¹¹⁾.

In meta-analyses, the overall intervention effect is summarised as weighted average of the (standardised) mean difference of individual studies. Usually, a random-effects model is used to combine the results, with the underlying assumption that there is not only one true effect size, but a distribution of true intervention effects across studies. Differences in effect size may vary by sex, age, geographic location, etc. If it is assumed that individual studies are estimating one common true effect size and differences are explained by sampling errors, a fixed-effect model is used⁽²³⁾. When there is clinical and statistical heterogeneity, a random-effects model should be the first choice. In the random-effects model, the true effect could vary from study to study. The random-effects method and the fixed-effect method will give identical results when there is no statistical heterogeneity among the studies⁽¹¹⁾. Summary estimates with their corresponding 95 % CI can be presented in a forest plot⁽²⁴⁾.

RCT in nutrition research are often prone to inherent methodological constraints. They sometimes cannot be controlled with true placebos, but rather by a limitation of certain aspects of nutrient compositions, food groups or dietary patterns. Other limitations include the lack of double blinding, poor compliance and adherence, cross-over bias, and high drop-out rates. Failure of allocation concealment, blinding and follow-up losses are well-established limitations of RCT⁽²⁵⁾. Low-quality RCT may lead to an overestimation of intervention effect estimates and raise heterogeneity⁽²⁶⁾. Assessing the risk of

bias/study quality/study limitations of individual RCT included in a meta-analysis is highly recommended, and sensitivity analyses excluding high risk of bias RCT should be conducted^(11,13). The risk of bias tool by the Cochrane collaboration takes the following items into account: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment personnel, incomplete outcome and selective reporting. The risk of bias for each item is expressed simply as low risk, high risk or unclear risk of bias⁽²⁷⁾. A previous analysis of fifty randomly selected meta-analyses of RCT⁽²⁸⁾ showed that 70 % applied the risk of bias assessment tool by the Cochrane collaboration, 10 % the Jadad scale⁽²⁹⁾, 14 % reported no risk of bias/study quality/study limitations item, 4 % applied their own score and one study used the Rosendal scale⁽³⁰⁾.

A promising new evidence-synthesis method for intervention studies is network meta-analysis (NMA), which is an extension of pairwise meta-analysis that enables a simultaneous comparison of multiple interventions, forming a connected network while preserving the internal randomisation of individual trials. NMA combines direct (e.g. from trials comparing directly two interventions) and indirect (e.g. from a connected root via one more intermediate comparators) evidence in a network of trials (Fig. 1)^(31–33). For example, in Fig. 1, none of the studies have compared intervention B (whole grains) with intervention C (nuts), but each has been compared with a common intervention A (refined grains), then we assume an indirect comparison of B and C on the direct comparison of B and A and the direct comparison of C and A. In this way, it enables inference about every possible comparison between a pair of interventions in the network even when some comparisons have never been evaluated in a trial. By conducting NMA, it is possible to derive a relative ranking of the different intervention for each outcome using the distribution of the ranking probabilities and the surface under the cumulative ranking curves⁽³⁴⁾. A fundamental assumption of NMA, often called the transitivity

assumption, is that trials comparing different sets of interventions should be similar enough in all characteristics that may affect the outcome^(35–37). To evaluate the assumption of transitivity, the distribution of potential effect modifiers (e.g. in Fig. 1, changes in body weight, age, duration of diabetes) across the available direct comparisons should be compared. To evaluate the presence of statistical inconsistency (i.e. disagreement between the different sources of evidence), the loop-specific approach (to detect loops of evidence that might present important inconsistency)⁽³⁸⁾, as well as the side-splitting approach (to detect comparisons for which direct estimates disagree with indirect evidence from the entire network)⁽³⁹⁾ should be applied.

Specific features of meta-analyses of cohort studies

Effect estimates in observational studies mostly refer to binary or count outcomes (e.g. incidence of a disease, mortality or prevalence) and are expressed mostly as hazard ratios or OR as an estimate of relative risk. In nutritional epidemiology, three types of meta-analysis regarding the combination of estimates are recommended.

Usually, in a first step, a high v. low meta-analysis is conducted. Here, the summary risk estimate with the corresponding 95 % CI for a specific outcome (e.g. incidence of a chronic disease) is calculated by comparing high v. low intake of a single food or food group by applying a random-effects model. As described earlier, the random-effects model assumes that the true effect may differ between studies and is more appropriate in nutritional epidemiology. The natural logarithm of the risk estimate is calculated for each study and weighted according to the method of DerSimonian and Laird⁽⁴⁰⁾. The high v. low meta-analysis provides an overview about the average risk of high intake of a specific food or food group compared with low intake regarding the outcome of interest. One of the major limitations of high v. low meta-analysis includes the comparability of the level of exposure categories across studies because intake categories generated in the original studies are not always comparable between them.

Thus, meta-analyses should not solely focus on 'simple' high v. low analysis, but also examine the summary effect for dose–response relations. In this analysis, the association between a dietary factor, measured as a continuous variable, and risk of the outcome of interest is investigated by performing a meta-analysis of the dose–response relation from each study. If original studies do not report on dose–response relations, the slope (linear trend and 95 % CI) for each study can be estimated using the method of generalised least squares for trend estimation proposed by Greenland and Longnecker⁽²¹⁾ and implemented by Orsini *et al.*⁽⁴¹⁾. In this case, information on the risk estimates with corresponding 95 % CI, the quantified exposure value and the distribution of cases and person-years (or non-cases) is required for at least three categories of the exposure. Missing information on the distribution of person-years or non-cases can be estimated if studies provide the number of total cases in addition to total person-years or the number of




Fig. 1. (Colour online) Example of a network diagram. The size of the nodes is proportional to the total number of participants allocated to each dietary approach and the thickness of the lines is proportional to the number of studies evaluating each direct comparison. SSB, sugar-sweetened beverages.

total participants plus follow-up period^(42,43). If studies report ranges of the exposure categories instead of the mean value, the mid-point between the lower and upper limits for each category can be calculated. For open categories (e.g. the highest quantile), a similar range to the adjacent category can be assumed.

Finally, to explore the shape of the diet-disease risk association, a non-linear dose-response meta-analysis can be performed for instance by using fractional polynomial models, or restricted cubic spline regression models^(44,45). Non-linearity of the association can be visually evaluated in graphs and by using a likelihood ratio test⁽⁴¹⁾.

Well-designed cohort studies provide important evidence with complementary strength (decade long exposures in large sample size of general populations with hard endpoints) and limitations (residual confounding and measurement error) as well. Ascertainment of exposure, adjustment factors, assessment of outcome and adequacy of follow-up are important challenges in conducting these studies.

Similar to meta-analyses of RCT, assessment of the risk of bias/study quality/study limitations of individual cohort studies included in a meta-analysis is important⁽¹⁴⁾. A previous analysis of fifty randomly selected meta-analyses of cohort studies⁽²⁸⁾ showed that 40 % of these meta-analyses applied no quality assessment score and 38 % used the Newcastle Ottawa Scale (points range 0–9), while the remaining 22 % applied a variety of less well-known tools⁽⁴⁶⁾.

Recently, we proposed a risk of bias assessment of cohort studies that takes into account ascertainment of exposure such as usual dietary intake, adjustment factors, assessment of outcome and adequacy of follow-up⁽²⁸⁾:

Usual dietary intake (e.g. long-term average) cannot usually be observed directly. Hence, in nutritional studies, dietary intake is mostly assessed by self-report instruments. The most prominent assessment instruments are FFQ, food record, 24 h dietary recall and dietary screener. All self-report dietary assessment instruments are prone to different types of measurement error and therefore can lead to biased risk estimates and loss of power⁽⁴⁷⁾. The risk of bias depends on the applied dietary assessment instrument, which is determined by the study design and study aim. In our risk of bias assessment tool, we proposed a low risk of bias rating for validated and calibrated FFQ, multiple 24 h dietary recalls and food records. Conversely, non-validated FFQ and single 24 h dietary recalls should be rated with a high risk of bias⁽²⁸⁾. A useful overview and description of the applicability of most prominent dietary assessment instruments is given in the Dietary Assessment Primer⁽⁴⁸⁾. In cohort studies, covariate adjustment is done to address confounding and other sources of bias (e.g. selection bias) or to increase precision in a diet-health outcome model. Therefore, the choice of an adequate set of adjusting variables depends on the assumed relationship between the exposure, the outcome and adjusting variables as well as the purpose of the statistical analyses. As in nutritional observational studies many confounding factors are often assumed to be present, we simplified the risk

of bias by counting the number of adjusting variables, rating low risk of bias for models with two or more adjusting variables. This simplification is based on the assumption that the adjustment variables of the studies that have been carried out are reasonable. It is important to remind that different adjustment sets can lead to different study results. A cohort study is rated with a low risk of bias for the assessment of outcome if the study provides record linkage (International Classification of Diseases codes), accepted clinical criteria or if assessment was blinded or independent. Conversely, self-reported and no assessment of study outcomes was rated as having a high risk of bias. Taking into account adequacy of follow-up we recommend for a rating of low risk of bias, a median follow-up of, e.g. ≥ 10 years for CVD, and ≥ 5 years for T2D.

Credibility of the evidence within meta-analyses

We recently developed the NutriGrade scoring system (maximum of ten points), to evaluate the trustworthiness (credibility) of evidence for the effect/association of a dietary factor and the outcome of interest⁽²⁸⁾.

Compared with the well-established Grading of Recommendations Assessment, Development and Evaluation approach, NutriGrade differs in the following aspects: it gives more weight to the evaluation of cohort study designs, because such design is important for the investigation of diet-disease relations; it assesses nutrition-specific aspects, such as dietary assessment methods and their validation, calibration of FFQ, and the assessment of diet-associated biomarkers; finally, it also considers the conflict of interest and funding bias as a separate item.

NutriGrade is based on the following seven items for RCT: (1) risk of bias, study quality, study limitations (maximum 3 points); (2) precision (maximum 1 point); (3) heterogeneity (maximum 1 point); (4) directness (maximum 1 point); (5) publication bias (maximum 1 point); (6) funding bias (maximum 1 point); (7) study design (+2 points); and the following eight items for cohort studies: (1) risk of bias, study quality, study limitations (maximum 2 points); (2) precision (maximum 1 point); (3) heterogeneity (maximum 1 point); (4) directness (maximum 1 point); (5) publication bias (maximum 1 point); (6) funding bias (maximum 1 point); (7) effect size (maximum 2 points); and (8) dose-response relations (maximum 1 point).

To evaluate and interpret the meta-evidence, we recommend four categories based on this scoring system: high confidence in the effect estimates (≥ 8 points); moderate confidence in the effect estimates (6 to < 8 points); low confidence in the effect estimates (4 to < 6 points); very low confidence in the effect estimates (0 to < 4 points).

There is also a need to evaluate the credibility of NMA evidence in a systematic way. The confidence in NMA (<http://cinema.ispm.ch/>) framework has been developed to judge the confidence that can be placed in the results obtained from a NMA by adapting and extending the Grading of Recommendations Assessment, Development

and Evaluation approach domains (study limitations, inconsistency, indirectness, imprecision and publication bias). The system is transparent and applicable to any network structure⁽⁴⁹⁾.

Evaluating the methodological quality of meta-analyses

AMSTAR, a measurement tool to assess systematic reviews, is one of the most widely used instruments to assess the methodological quality of systematic reviews, and consists of eleven-item questionnaire (e.g. provision of an *a priori* design, use of two independent reviewers for data extraction, assessment and documentation of study quality, assessment of publication bias, conflict of interest statement) that asks reviewers to answer yes, no or can't answer, and was published in 2007 (maximum score of 11)⁽⁵⁰⁾. An umbrella review of fourteen meta-analyses investigating the impact of nut intake on biomarkers of CVD showed that ten out of fourteen reported an AMSTAR score <8⁽⁵¹⁾. Two recent overviews of reviews suggest that current meta-analyses/systematic reviews evaluating the association of Mediterranean diet on health outcomes varied strongly regarding their methodologic quality (total score 4–20), assessed with a modified AMSTAR quality scale (maximum score 22)^(52,53). Recently, an update of the AMSTAR has been published (AMSTAR 2). This update is based on sixteen items and has an overall rating based on weaknesses in critical domains⁽⁵⁴⁾.

A new tool for assessing the risk of bias in systematic reviews (the ROBIS tool) mainly covers research questions relating to effectiveness, aetiology, diagnosis and prognosis⁽⁵⁵⁾. Important flaws and limitations in the design, conduct or analysis of a systematic review will influence the results or conclusions of the review. It is important to note that a systematic review can be judged with a low risk of bias, even if the included studies were rated with a high risk of bias, as long as the systematic review has rigorously assessed the risk of bias of the included studies when summarising the evidence. The tool includes three phases: the first focuses on the relevance of the research question (define the participants, interventions/exposure, comparisons, outcomes and study design criteria) (which is optional); the second evaluates potential bias (study eligibility criteria, identification and selection of studies, data collection and study appraisal, and synthesis and findings of the review process) and in the third phase, the risk of bias is judged⁽⁵⁵⁾.

Quantification of health impact of diet–disease relations

Given the multi-faceted nature of population health, the health impact or burden of disease and risk factors can be described by a variety of indicators⁽⁵⁶⁾. Typical health impact indicators include cause-specific mortality rates, incidence rates and prevalence ratios. These metrics however do not allow for a comprehensive comparison or aggregation of health outcomes. Indeed, these unidimensional measures of population health only quantify the effects of either mortality or morbidity, thus impeding comparisons between fatal and disabling conditions. Furthermore, they only take into account disease

occurrence, without quantifying disease severity. In response to these limitations, several authors have developed summary measures of population health that integrate multiple dimensions of health impact. Driven by the influential GBD studies, led by the WHO and the Institute for Health Metrics and Evaluation, the DALY has become the key summary measure of population health for quantifying burden of disease^(57,58). The DALY is a health gap measure, quantifying the health gap from a life lived in perfect health as the number of years of healthy life lost due to illness (years lived with disability, YLD) and premature death (years of life lost, YLL):

$$\text{YLD} = \text{number of incident cases} \times \text{duration until remission or death} \times \text{disability weight},$$

$$\text{YLL} = \text{number of deaths} \times \text{residual life expectancy at the age of death}.$$

An alternative formula for calculating YLD follows an incidence rather than a prevalence perspective⁽⁵⁹⁾:

$$\text{YLD} = \text{number of prevalent cases} \times \text{disability weight}.$$

Two complementary approaches may be defined for quantifying the disease burden associated with dietary or other risk factors⁽⁶⁰⁾. In the bottom-up approach, dose–response relations of dietary exposure and health outcomes are combined in a risk assessment model to predict the expected disease burden⁽⁶¹⁾. The top-down approach starts from available epidemiological data and associates health states with the concerned risk factor at an individual level (e.g. categorical attribution) or at a population level (e.g. comparative risk assessment). In the GBD studies, comparative risk assessment is the standard approach for quantifying diet-related health problems^(3,62,63). This approach is based on the calculation of population-attributable fractions (PAF), which represent the proportion of risk that would be averted if exposure would have been limited to an ideal exposure level. Estimates of the attributable burden (AB) for risk–outcome pairs are obtained by multiplying the overall burden estimate with the PAF:

$$\text{AB} = \text{DALY} \times \text{PAF}.$$

The PAF for a continuous risk factor, such as consumption of fruit and vegetables quantified in terms of g/d, is defined as follows:

$$\text{PAF} = \frac{\int_{x=l}^u \text{RR}(x)P(x)dx - \text{RR}(\text{TMREL})}{\int_{x=l}^u \text{RR}(x)P(x)dx},$$

where $\text{RR}(x)$ is the relative risk as a function of exposure level x , which ranges between a lower bound l and an upper bound u ; $P(x)$ is the prevalence of exposure at level x ; and TMREL is the theoretical minimum-risk exposure level.

In a similar way, the PAF for a discrete risk factor which can take on u different distinct exposure levels, such as consumption of fruit and vegetables quantified

as specific consumption levels, is defined as:

$$PAF = \frac{\sum_{x=1}^u RR(x)P(x) - RR(TMREL)}{\sum_{x=1}^u RR(x)P(x)}$$

The most recent iteration of the GBD project is the GBD 2016, which provides estimates for the period 1990–2016^(3,63). By providing estimates on the burden of dietary risk factors, the GBD project allows for a direct identification and ranking of diet-related health problems at a global, regional or national level^(3,63). The GBD 2016 estimates can be explored in an interactive way via <http://vizhub.healthdata.org/gbd-compare/>.

According to the GBD 2016 study, dietary risk factors were associated with nearly 10 % of the GBD. The major diet-associated disease clusters were CVD (8.0 % of total DALY), diabetes (1.0 % of total DALY) and neoplasms (0.6 % of total DALY). The group of dietary risk factors comprised fifteen individual dietary risks, with diets low in whole grains and diets low in fruit as major contributors (Fig. 2).

In this context, attention should be given to the potential dependencies between measures of effect/association if the overall impact of an exposure, e.g. a food, is compared across health outcomes. For example, a certain food group (exposure) having an impact on multiple, dependent health outcomes such as mortality and CVD, where CVD also contributes to mortality itself. The current meta-analyses aggregate the study results for a single outcome and assume that the measured effect/association are independent across all health outcomes⁽⁶⁴⁾. However, this assumption is not realistic and it can be assumed that health outcomes correlate with each other⁽⁶⁵⁾. It could be shown that correlations between health outcomes result in dependences between measures of effect/association across health outcomes that could lead to biased estimates⁽⁶⁶⁾, underestimated standard error of the effect estimate (leading to narrow CI) and incorrect rejection of the null hypothesis⁽⁶⁷⁾.

A number of approaches have been proposed to meta-analyse dependent effect sizes. If the correlations between effect sizes are available, the dependence can be mathematically modelled using approaches proposed by means of a multivariate model for the

meta-analysis^(20,68–70). However, as correlations among measurements of effect are not often reported in the studies, a meta-analysis using a multi-variate approach may be challenging. Alternatively, a three-level meta-analysis can be used when correlations between the measurements of effect are not known^(71,72). A three-level meta-analysis is the extension of the two-level meta-analysis in which the within-study-dependent effect sizes are clustered at level 2 and the between-study effects are estimated at level 3. Other possible approaches when correlations among effect estimates are not known include robust variance estimation⁽⁷³⁾ and methods of moments^(74,75). Many of these approaches are available in the statistical software package R^(64,76,77).

Current evidence for food-based dietary guidelines

Meta-analyses of randomised controlled trials

Compared with the tremendous number of published meta-analyses of observational studies on the association between food groups and risk of chronic diseases, the number of meta-analyses of RCT investigating the effect of food groups on metabolic risk factors is very low. Although very large long-term RCT have been conducted, e.g. the Women's Health Initiative Dietary Modification Trial or the Prevención con Dieta Mediterránea trial^(78,79), most dietary intervention studies are of short-term duration with small sample sizes, and focus on dietary approaches (e.g. low-carbohydrate diet, Mediterranean diet), and/or dietary supplements (e.g. vitamins, minerals) often in high-risk populations, and did not often investigate the effects of single-food groups. Nevertheless, some meta-analyses on the effects of food groups on cardiovascular risk factors have been published (Table 2).

A meta-analysis of twenty-four RCT showed that the consumption of whole-grain diets compared with control diets reduces LDL-cholesterol (LDL-C) and total cholesterol (TC), but not HDL-cholesterol (HDL-C) or TAG⁽⁸⁰⁾, whereas other meta-analyses showed a reduction in fasting glucose (FG), but no effect on diastolic blood pressure and systolic blood pressure (SBP), respectively, or body weight^(81,82). A Cochrane review of ten RCT




Fig. 2. (Colour online) Contribution of dietary risk factors to the global burden of disease, 2016. DALY, disability-adjusted life years.

Table 2. Evidence summary from meta-analyses of intervention trials investigating the effects between food groups and metabolic risk factors^(80–101)

	Body weight	Total cholesterol	LDL-cholesterol	HDL-cholesterol	TAG	DBP	SBP	Fasting glucose	HbA1c	CRP
Whole grains	↔	↓	↓	↔	↓	↔	↔	↓	NA	NA
Fruit and vegetables	↔	↔	↓	↔	↔	↓	↓	↔	NA	NA
Nuts	↔	↓	↓	↔	↓	↔	↓	↓	↓	↔
Legumes	↓	↓	↓	↔	↔	↔	↓	↓	NA	↓
Eggs	NA	↑	↑	↑	↔	NA	NA	NA	NA	NA
Dairy	↔	NA	↔	↔	NA	↔	↔	NA	NA	↔
Fish	NA	↔	↔	↑	↓	↔	↔	↔	NA	↔
Red meat	NA	↔	↔	↔	↔	↔	↔	NA	NA	NA
Sugar-sweetened beverages	↑	NA	NA	NA	NA	NA	NA	NA	NA	NA

CRP, C-reactive protein; DBP, diastolic blood pressure; HbA1c, glycosylated Hb; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; NA, not assessed; SBP, systolic blood pressure.

↔ No effect with increased intake; ↑ increased with higher intake; ↓ reduction with increased intake.

focusing on interventions to increase fruit and vegetable consumption showed reductions in diastolic blood pressure, SBP and LDL-C, but analyses were based on only two trials⁽⁸³⁾. Other meta-analyses reported no effect on HDL-C, TAG, FG or body weight^(84,85). Meta-analyses investigating the effects of nut consumption reported reductions in TC, LDL-C, TAG, diastolic blood pressure, FG and glycosylated Hb (both in T2D patients)^(86–88), but no effects on body weight, HDL-C, SBP and C-reactive protein^(87,89,90). Focusing on legumes, one meta-analysis of ten RCT indicated that interventions to increase the intake of legumes were associated with decreased TC and LDL-C levels compared with a control group⁽⁹¹⁾, others reported reductions in C-reactive protein, SBP and FG^(92,93), but no effects on body weight⁽⁹²⁾. Evidence from meta-analyses of intervention trials showed that higher consumption of sugar-sweetened beverages (SSB) leads to a considerable increase in body weight^(94,95).

Considering food groups of animal origin, higher consumption of eggs increased TC, LDL-C and HDL-C, but not TAG compared with control diets low in egg consumption⁽⁹⁶⁾. A meta-analysis of RCT showed that higher dairy intake has no significant effect on change in SBP for interventions over 1–12 months⁽⁹⁷⁾, and other meta-analyses showed no significant effects of either high- or low-fat dairy products on cardiovascular risk factors and body weight compared with a diet with lower amount of dairy^(98,99). A recent meta-analysis showed that there is evidence indicating that consuming oily fish leads to significant improvements in two important biomarkers of cardiovascular risk, such as TAG and HDL-C, whereas no effects were observed for TC, LDL-C, diastolic blood pressure, SBP, FG and C-reactive protein⁽¹⁰⁰⁾. Regarding meat intake, consumption of more than a half serving of total red meat daily does not influence blood lipids and lipoproteins or blood pressure compared with lower red meat intakes⁽¹⁰¹⁾.

Meta-analyses of cohort studies

A series of dose–response meta-analyses investigated the association between twelve *a priori*-defined food groups

and risk of all-cause mortality, CHD, stroke, heart failure, T2D, colorectal cancer and hypertension (Table 3)⁽¹⁰²⁾. The meta-analysis for all-cause mortality included 100 cohort studies, and showed that higher intakes of whole grains, vegetables, fruit, nuts and fish were associated with lower risk of premature death, whereas higher intakes of red and processed meat and SSB were associated with higher overall mortality risk in the linear dose–response meta-analysis⁽¹⁰³⁾. Focusing on T2D, the optimal consumption of risk-decreasing foods (two servings/d whole grains; two to three servings/d vegetables; two to three servings/d fruit; three servings/d dairy) resulted in a 42 % reduction of T2D risk, and consumption of risk-increasing foods (one serving/d eggs, two servings/d red meat, four servings/d processed meat and three servings/d SSB) was associated with a 3-fold T2D risk, compared with non-consumption of these food groups⁽¹⁰⁴⁾. Regarding CVD, 123 cohort studies were identified. An inverse association was present for whole grains, vegetables and fruit, nuts and fish consumption, while a positive association was present for egg, red meat, processed meat and SSB consumption in the linear dose–response meta-analysis⁽¹⁰⁵⁾. Taking into account twenty-eight reports investigating the association between the twelve food groups and the risk of hypertension, we could show that optimal intakes of whole grains, fruit, nuts, legumes and dairy were associated with a 44 % risk reduction, whereas high consumption of red and processed meat and SSB was related with a 33 % increased risk of hypertension⁽¹⁰⁶⁾. Eighty-six cohort studies were included in the meta-analysis investigating the association between the twelve food groups and colorectal cancer risk. Optimal consumption of risk-decreasing foods (six servings/d whole grains, vegetables and dairy; and three servings/d fruit) results in a 56 % risk reduction of colorectal cancer, whereas consumption of risk-increasing foods of two servings/d red meat and four servings/d processed meat was associated with a 1.8-fold increased risk⁽¹⁰⁷⁾. Previous meta-analyses of cohort studies comparing high v. low dietary intake reported a significant lower risk of weight gain for higher intake of whole grain products⁽⁸¹⁾ and a lower risk of adiposity for higher intake of fruit and vegetables

Table 3. Evidence summary from meta-analyses of cohort studies investigating the association between twelve food groups and the risk of major chronic disease^(81,94,102–110)

	All-cause mortality	CHD	Stroke	Heart failure	Type 2 diabetes	Hypertension	Colorectal cancer	Overweight/obesity/weight gain
Whole grains (per 30 g/d)	↓	↓	↔	↓	↓	↓	↓	↓*
Refined grains (per 30 g/d)	↔	↔	↔	↔	↔	↔	NA	NA
Vegetables (per 100 g/d)	↓	↓	↓	↓	↓	↔	↓	↓*
Fruit (per 100 g/d)	↓	↓	↓	↔	↓	↓	↓	↓*
Nuts (per 28 g/d)	↓	↓	↔	↔	↔	↓	↔	NA
Legumes (per 50 g/d)	↓	↓	↔	NA	↔	↔	↔	NA
Eggs (per 50 g/d)	↑	↔	↔	↑	↔	↓	↔	NA
Dairy (per 200 g/d)	↔	↔	↓	↑	↓	↓	↓	↓*
Fish (per 100 g/d)	↓	↓	↓	↓	↔	↔	↓	NA
Red meat (per 100 g/d)	↑	↑	↑	↑	↑	↑	↑	↑*
Processed meat (per 50 g/d)	↑	↑	↑	↑	↑	↑	↑	↑*
Sugar-sweetened beverages (per 250 ml/d)	↑	↑	↑	↑	↑	↑	↔	↑ (per 330 ml/d)

*High v. low analysis; ↔ no association between food group intake and chronic disease; ↑ increased risk with higher intake; ↓ decreased risk with higher intake; NA, not assessed. The thickness of arrows corresponds to the quality of evidence: = high; = moderate; = low; = very low.

and dairy^(108,109). Another meta-analysis of observational studies reported consistent evidence that both red and processed meat intake was positively associated with the risk of obesity⁽¹¹⁰⁾. Consistent evidence from another meta-analysis of cohort studies showed that high consumption of SSB is associated with a higher risk of weight gain⁽⁹⁴⁾.

Credibility of the evidence

Table 3 gives an overview of the NutriGrade judgement on the association between intake of food groups and the risk of chronic diseases derived from meta-analyses of cohort studies^(103–107). The credibility of evidence was rated high for the inverse association between whole grain intake and the risk of all-cause mortality and T2D, as well as for the positive association between red meat, processed meat and SSB and the risk of T2D. For these associations, further research probably will not change our confidence in the estimates. Most of the evidence for the associations between the twelve food groups and chronic disease risk is based on low and moderate quality of evidence, and further research could provide or add (important) evidence.

Conclusions

FBDG are the preferred approach to guide the population regarding their dietary habits, and such guidelines should be based on a high grade of evidence as requested in many other areas of public health practice. The most straightforward approach to generate evidence is meta-analysing published data based on a careful phrasing of the research question (participants, interventions/exposure, comparisons, outcomes and study design). Hereby, it is important

to generate evidence by applying meta-analytical methods to both major study designs (RCT and cohort studies). Regarding credibility of evidence assessment, risk of bias and other characteristics of the meta-analyses should be assessed, rated and scored (NutriGrade).

Evidence from large meta-analyses of cohort studies suggest that higher intake of plant origin food groups such as whole grains, fruit, vegetables, nuts and legumes are associated with a lower risk of chronic diseases, whereas higher intake of red and processed meat and SSB are associated with increased risk of T2D, CVD and hypertension. Although the evidence from meta-analyses of RCT is much more incomplete, it was shown that several food groups such as whole grains, fruit and vegetables, nuts, legumes and fish had a beneficial effect on the cardio-metabolic risk profile. To further contribute to the evaluation of the complete picture of FBDG, we propose conducting NMA of RCT considering and rating different food groups in one analysis. Moreover, the health impact of the different foods can be calculated by DALY for the various clinical outcomes and the overall results compared across the food groups and across approaches that consider the correlations between health outcomes. For future FBDG, we recommend to implement evidence from pairwise and NMA and to quantify the health impact of diet-disease relationships.

Financial Support

None.

Conflict of Interest

None.

Authorship

L. S., S. S., B. D., K. I., S. K., and H. B. wrote the first draft of the paper. All authors contributed to the paper's content and made suggestions and edits to drafts. All authors have read and approved the final version of the paper.

References

- Chiuve SE, McCullough ML, Sacks FM *et al.* (2006) Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. *Circulation* **114**, 160–167.
- Ford ES, Bergmann MM, Kroger J *et al.* (2009) Healthy living is the best revenge: findings from the European prospective investigation into cancer and nutrition-potsdam study. *Arch Intern Med* **169**, 1355–1362.
- GBD 2016 Risk Factors Collaborators (2017) Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the global burden of disease study 2016. *Lancet* **390**, 1345–1422.
- European Food Safety Authority (2010) Scientific opinion on establishing food-based dietary guidelines. *EFSA J* **8**, 1460.
- Food and Agriculture Organization, WHO (World Health Organization), eds. *World Declaration and Plan of Action for Nutrition*. Rome: FAO/WHO International Conference on Nutrition.
- Lichtenstein AH, Yetley EA & Lau J. (2009) In *Application of Systematic Review Methodology to the Field of Nutrition: Nutritional Research Series*, vol. 1. pp. 1–36. Rockville, MD: AHRQ Technical Reviews.
- Ioannidis JP (2016) The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. *Milbank Q* **94**, 485–514.
- Page MJ & Moher D (2016) Mass production of systematic reviews and meta-analyses: an exercise in mega-silliness? *Milbank Q* **94**, 515–519.
- Cook DJ, Mulrow CD & Haynes RB (1997) Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med* **126**, 376–380.
- Larsen PO & von Ins M (2010) The rate of growth in scientific publication and the decline in coverage provided by science citation index. *Scientometrics* **84**, 575–603.
- Higgins J & Green S (2011) *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011]. The Cochrane Collaboration, 2011.
- Bastian H, Glasziou P & Chalmers I (2010) Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? *PLoS Med* **7**, e1000326.
- Moher D, Liberati A, Tetzlaff J *et al.* (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* **6**, e1000097.
- Stroup DF, Berlin JA & Morton SC (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* **283**, 2008–2012.
- Schwingshackl L, Chaimani A, Hoffmann G *et al.* (2018) A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. *Eur J Epidemiol* **33**, 157–170.
- Schwingshackl L, Chaimani A, Hoffmann G *et al.* (2017) Impact of different dietary approaches on glycaemic control and cardiovascular risk factors in patients with type 2 diabetes: a protocol for a systematic review and network meta-analysis. *Syst Rev* **6**, 57.
- Ioannidis JP, Patsopoulos NA & Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. *BMJ* **335**, 914–916.
- Egger M, Davey SG, Schneider M *et al.* (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* **315**, 629–634.
- Begg CB & Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. *Biometrics* **50**, 1088–1101.
- Gleser LJ & Olkin I (1994) Stochastically dependent effect sizes. In *The handbook of research synthesis*, pp. 339–355 [H Cooper and LV Hedges, editors]. New York: Russell Sage Foundation.
- Greenland S & Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *Am J Epidemiol* **135**, 1301–1309.
- Hamling J, Lee P, Weitkunat R *et al.* (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. *Stat Med* **27**, 954–970.
- Riley RD, Higgins JP & Deeks JJ (2011) Interpretation of random effects meta-analyses. *BMJ* **342**, d549.
- Lewis S & Clarke M (2001) Forest plots: trying to see the wood and the trees. *BMJ* **322**, 1479–1480.
- Bjelakovic G, Nikolova D, Gluud LL *et al.* (2012) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev* **3**, CD007176.
- Savovic J, Jones HE, Altman DG *et al.* (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Ann Intern Med* **157**, 429–438.
- Higgins JP, Altman DG, Gotzsche PC *et al.* (2011) The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **343**, d5928.
- Schwingshackl L, Knuppel S, Schwedhelm C *et al.* (2016) Perspective: NutriGrade: a scoring system to assess and judge the meta-evidence of randomized controlled trials and cohort studies in nutrition research. *Adv Nutr* **7**, 994–1004.
- Jadad AR, Moore RA, Carroll D *et al.* (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* **17**, 1–12.
- Khalesi S, Irwin C & Schubert M (2015) Flaxseed consumption may reduce blood pressure: a systematic review and meta-analysis of controlled trials. *J Nutr* **145**, 758–765.
- Schwingshackl L, Dias S & Hoffmann G (2014) Impact of long-term lifestyle programmes on weight loss and cardiovascular risk factors in overweight/obese participants: a systematic review and network meta-analysis. *Syst Rev* **3**, 130.
- Schwingshackl L, Dias S, Strasser B *et al.* (2013) Impact of different training modalities on anthropometric and metabolic characteristics in overweight/obese subjects: a systematic review and network meta-analysis. *PLoS ONE* **8**, e82853.
- Schwingshackl L, Missbach B, Dias S *et al.* (2014) Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. *Diabetologia* **57**, 1789–1797.

34. Salanti G, Ades AE & Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* **64**, 163–171.
35. Salanti G (2012) Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Res Synth Methods* **3**, 80–97.
36. Leucht S, Chaimani A, Cipriani AS *et al.* (2016) Network meta-analyses should be the highest level of evidence in treatment guidelines. *Eur Arch Psychiatry and Clin Neurosci* **266**, 477–480.
37. Mavridis D, Giannatsi M, Cipriani A *et al.* (2015) A primer on network meta-analysis with emphasis on mental health. *Evid Based Ment Health* **18**, 40–46.
38. Bucher HC, Guyatt GH, Griffith LE *et al.* (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol* **50**, 683–691.
39. Dias S, Welton NJ, Caldwell DM *et al.* (2010) Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* **29**, 932–944.
40. DerSimonian R & Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* **7**, 177–188.
41. Orsini N, Li R, Wolk A *et al.* (2012) Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. *Am J Epidemiol* **175**, 66–73.
42. Chene G & Thompson SG (1996) Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. *Am J Epidemiol* **144**, 610–621.
43. Aune D, Greenwood DC, Chan DS *et al.* (2012) Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. *Ann Oncol* **23**, 843–852.
44. Durrleman S & Simon R (1989) Flexible regression models with cubic splines. *Stat Med* **8**, 551–561.
45. Bagnardi V, Zamboni A, Quatto P *et al.* (2004) Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. *Am J Epidemiol* **159**, 1077–1086.
46. Wells GASB, O'Connell D, Peterson J *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf (accessed November 2015).
47. Freedman LS, Schatzkin A, Midthune D *et al.* (2011) Dealing with dietary measurement error in nutritional cohort studies. *J Natl Cancer Inst* **103**, 1086–1092.
48. National Cancer Institute (2017) Dietary Assessment Primer, Section Name. National Institutes of Health, National Cancer Institute. <https://dietassessmentprimer.cancer.gov/> (accessed December 2017).
49. Salanti G, Del Giovane C, Chaimani A *et al.* (2014) Evaluating the quality of evidence from a network meta-analysis. *PLoS ONE* **9**, e99682.
50. Shea BJ, Grimshaw JM, Wells GA *et al.* (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol* **7**, 10.
51. Schwingshackl L, Hoffmann G, Missbach B *et al.* (2017) An umbrella review of nuts intake and risk of cardiovascular disease. *Curr Pharm Des* **23**, 1016–1027.
52. Huedo-Medina TB, Garcia M, Bihuniak JD *et al.* (2016) Methodologic quality of meta-analyses and systematic reviews on the Mediterranean diet and cardiovascular disease outcomes: a review. *Am J Clin Nutr* **103**, 841–850.
53. Dinu M, Pagliai G, Casini A *et al.* (2017) Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. *Eur J Clin Nutr* **72**, 30–43.
54. Shea BJ, Reeves BC, Wells G *et al.* (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* **358**, j4008.
55. Whiting P, Savovic J, Higgins JP *et al.* (2016) ROBIS: a new tool to assess risk of bias in systematic reviews was developed. *J Clin Epidemiol* **69**, 225–234.
56. Devleeschauwer B, Maertens de Noordhout C, Smit GS *et al.* (2014) Quantifying burden of disease to support public health policy in Belgium: opportunities and constraints. *BMC Public Health* **14**, 1196.
57. Devleeschauwer B, Havelaar AH, Maertens de Noordhout C *et al.* (2014) Calculating disability-adjusted life years to quantify burden of disease. *Int J Public Health* **59**, 565–569.
58. Murray CJ (1994) Quantifying the burden of disease: the technical basis for disability-adjusted life years. *Bull World Health Organ* **72**, 429–445.
59. Murray CJ, Ezzati M, Flaxman AD *et al.* (2012) GBD 2010: design, definitions, and metrics. *Lancet* **380**(9859), 2063–2066.
60. Devleeschauwer B, Haagsma JA, Angulo FJ *et al.* (2015) Methodological framework for world health organization estimates of the global burden of foodborne disease. *PLoS ONE* **10**, e0142498.
61. Institute of Medicine Food F. (2007) *The National Academies Collection: Reports funded by National Institutes of Health. Nutritional Risk Assessment: Perspectives, Methods, and Data Challenges, Workshop Summary*. Washington, DC: National Academies Press (US) National Academy of Sciences.
62. Micha R, Kalantarian S, Wirojratana P *et al.* (2012) Estimating the global and regional burden of suboptimal nutrition on chronic disease: methods and inputs to the analysis. *Eur J Clin Nutr* **66**, 119–129.
63. GBD 2016 DALYs and HALE Collaborators (2017) Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* **390**, 1260–1344.
64. Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. *J Stat Softw* **36**, 1–48.
65. Thompson CG & Becker BJ (2014) The impact of multiple endpoint dependency on Q and I(2) in meta-analysis. *Res Synth Methods* **5**, 235–253.
66. Riley RD (2009) Multivariate meta-analysis: the effect of ignoring within-study correlation. *J R Stat Soc: Series A (Stat Soc)* **172**, 789–811.
67. Becker BJ. (2000) Multivariate meta-analysis. In *Handbook of Applied Multivariate Statistics and Mathematical Modeling*, pp. 499–525 [HEA Tinsley and ED Brown, editors]. Orlando: Academic Press.
68. Raudenbush SW, Becker BJ & Kalaian H (1988) Modeling multivariate effect sizes. *Psychol Bull* **103**, 111.
69. Rosenthal R & Rubin DB (1986) Meta-analytic procedures for combining studies with multiple effect sizes. *Psychol Bull.* **99**, 400–406.
70. Borenstein M, Hedges LV, Higgins J *et al.* (2009) Multiple outcomes or time-points within a study. *Intro Meta-Anal* **225–238**.

71. Konstantopoulos S (2011) Fixed effects and variance components estimation in three-level meta-analysis. *Res Synth Methods* **2**, 61–76.
72. Cheung MW-L (2014) Modeling dependent effect sizes with three-level meta-analyses: a structural equation modeling approach. *Psychol Methods* **19**, 211–229.
73. Hedges LV, Tipton E & Johnson MC (2010) Robust variance estimation in meta-regression with dependent effect size estimates. *Res Synth Methods* **1**, 39–65.
74. Jackson D, White IR & Riley RD (2013) A matrix-based method of moments for fitting the multivariate random effects model for meta-analysis and meta-regression. *Bio J* **55**, 231–245.
75. Chen Y, Cai Y, Hong C *et al.* (2016) Inference for correlated effect sizes using multiple univariate meta-analyses. *Stat Med* **35**, 1405–1422.
76. Gasparrini A, Armstrong B & Kenward M (2012) Multivariate meta-analysis for non-linear and other multi-parameter associations. *Stat Med* **31**, 3821–3839.
77. Cheung MW-L (2015) MetaSEM: an R package for meta-analysis using structural equation modeling. *Front Psychol* **5**, 1521.
78. Estruch R, Ros E, Salas-Salvado J *et al.* (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* **368**, 1279–1290.
79. Howard BV, Manson JE, Stefanick ML *et al.* (2006) Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. *JAMA* **295**, 39–49.
80. Hollaender PL, Ross AB & Kristensen M (2015) Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. *Am J Clin Nutr* **102**, 556–572.
81. Ye EQ, Chacko SA, Chou EL *et al.* (2012) Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. *J Nutr* **142**, 1304–1313.
82. Pol K, Christensen R, Bartels EM *et al.* (2013) Whole grain and body weight changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. *Am J Clin Nutr* **98**, 872–884.
83. Hartley L, Igbinedion E, Holmes J *et al.* (2013) Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. *Cochrane Database Syst Rev* Cd009874.
84. Shin JY, Kim JY, Kang HT *et al.* (2015) Effect of fruits and vegetables on metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. *Int J Food Sci Nutr* **66**, 416–425.
85. Kaiser KA, Brown AW, Bohan Brown MM *et al.* (2014) Increased fruit and vegetable intake has no discernible effect on weight loss: a systematic review and meta-analysis. *Am J Clin Nutr* **100**, 567–576.
86. Musa-Veloso K, Paulionis L, Poon T *et al.* (2016) The effects of almond consumption on fasting blood lipid levels: a systematic review and meta-analysis of randomised controlled trials. *J Nutr Sci* **5**, e34.
87. Mohammadifard N, Salehi-Abargouei A, Salas-Salvado J *et al.* (2015) The effect of tree nut, peanut, and soy nut consumption on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. *Am J Clin Nutr* **101**, 966–982.
88. Vigiouliou E, Kendall CW, Blanco Mejia S *et al.* (2014) Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials. *PLoS ONE* **9**, e103376.
89. Flores-Mateo G, Rojas-Rueda D, Basora J *et al.* (2013) Nut intake and adiposity: meta-analysis of clinical trials. *Am J Clin Nutr* **97**, 1346–1355.
90. Neale EP, Tapsell LC, Guan V *et al.* (2017) The effect of nut consumption on markers of inflammation and endothelial function: a systematic review and meta-analysis of randomised controlled trials. *BMJ Open* **7**, e016863.
91. Bazzano LA, Thompson AM, Tees MT *et al.* (2011) Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis* **21**, 94–103.
92. Vigiouliou E, Blanco Mejia S, Kendall CW *et al.* (2017) Can pulses play a role in improving cardiometabolic health? Evidence from systematic reviews and meta-analyses. *Ann NY Acad Sci* **1392**, 43–57.
93. Salehi-Abargouei A, Saraf-Bank S, Bellissimo N *et al.* (2015) Effects of non-soy legume consumption on C-reactive protein: a systematic review and meta-analysis. *Nutrition* **31**, 631–639.
94. Malik VS, Pan A, Willett WC *et al.* (2013) Sugar-sweetened beverages and weight gain in children and adults: a systematic review and meta-analysis. *Am J Clin Nutr* **98**, 1084–1102.
95. Te Morenga L, Mallard S & Mann J (2012) Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. *BMJ* **346**, e7492.
96. Rouhani MH, Rashidi-Pourfard N, Salehi-Abargouei A *et al.* (2018) Effects of egg consumption on blood lipids: a systematic review and meta-analysis of randomized clinical trials. *J Am Coll Nutr* **37**, 99–110.
97. Ding M, Huang T, Bergholdt HK *et al.* (2017) Dairy consumption, systolic blood pressure, and risk of hypertension: Mendelian randomization study. *BMJ* **356**, j1000.
98. Benatar JR, Sidhu K & Stewart RA (2013) Effects of high and low fat dairy food on cardio-metabolic risk factors: a meta-analysis of randomized studies. *PLoS ONE* **8**, e76480.
99. Chen M, Pan A, Malik VS *et al.* (2012) Effects of dairy intake on body weight and fat: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **96**, 735–747.
100. Alhassan A, Young J, Lean MEJ *et al.* (2017) Consumption of fish and vascular risk factors: a systematic review and meta-analysis of intervention studies. *Atherosclerosis* **266**, 87–94.
101. O'Connor LE, Kim JE & Campbell WW (2017) Total red meat intake of ≥ 0.5 servings/d does not negatively influence cardiovascular disease risk factors: a systematically searched meta-analysis of randomized controlled trials. *Am J Clin Nutr* **105**, 57–69.
102. Schwingshackl L, Chaimani A, Bechthold A *et al.* (2016) Food groups and risk of chronic disease: a protocol for a systematic review and network meta-analysis of cohort studies. *Syst Rev* **5**, 125.
103. Schwingshackl L, Schwedhelm C, Hoffmann G *et al.* (2017) Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. *Am J Clin Nutr* **105**, 1462–1473.
104. Schwingshackl L, Hoffmann G, Lampousi AM *et al.* (2017) Food groups and risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. *Eur J Epidemiol* **32**, 363–375.
105. Bechthold A, Boeing H, Schwedhelm C *et al.* (2017) Food groups and risk of coronary heart disease, stroke and heart failure: a systematic review and dose-response meta-analysis



- of prospective studies. *Crit Rev Food Sci Nutr* [Epublication ahead of print version].
106. Schwingshackl L, Schwedhelm C, Hoffmann G *et al.* (2017) Food groups and risk of hypertension: a systematic review and dose-response meta-analysis of prospective studies. *Adv Nutr* **8**, 793–803.
107. Schwingshackl L, Schwedhelm C, Hoffmann G *et al.* (2017) Food groups and risk of colorectal cancer. *Int J Cancer* **142**, 1748–1758.
108. Schwingshackl L, Hoffmann G, Kalle-Uhlmann T *et al.* (2015) Fruit and vegetable consumption and changes in anthropometric variables in adult populations: a systematic review and meta-analysis of prospective cohort studies. *PLoS ONE* **10**, e0140846.
109. Schwingshackl L, Hoffmann G, Schwedhelm C *et al.* (2016) Consumption of dairy products in relation to changes in anthropometric variables in adult populations: a systematic review and meta-analysis of cohort studies. *PLoS ONE* **11**, e0157461.
110. Rouhani MH, Salehi-Abargouei A, Surkan PJ *et al.* (2014) Is there a relationship between red or processed meat intake and obesity? A systematic review and meta-analysis of observational studies. *Obes Rev* **15**, 740–748.